Alternatively open the App & go via the 'NHS - Continue to NHS login' button on the sign in page, but you may still have to request that your records are made available to view
Tirzepatide, a dual GLP-1 and GIP receptor agonist, has shown significant weight reduction in clinical trials, with patients losing up to 22% of body weight over 68 weeks
That's right, they're working to get there
Some patients may ask about switching from semaglutide to tirzepatide if weight loss slows, side effects become difficult, blood sugar goals change, or they are not seeing the desired response
Patients with T2DM, persons at risk for AD, had a significantly lower associated risk of AD after administered exenatide, liraglutide and dulaglutide ( Conclusion Increasing evidence suggests that anti-diabetes medicine, GLP-1R agonists, have multiple neuroprotective mechanisms in AD models, such as anti-inflammation, anti-oxidative stress, reducing A aggregation/deposition and tau protein hyperphosphorylation, reducing neuronal apoptosis and neurotoxicity, increasing cell proliferation and neurogenesis, increasing synaptic plasticity, and other beneficial effects
Our guide on whether tirzepatide works when semaglutide does not explores this scenario in detail
